Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CD22 CAR-T
- Development stage
- Unknown
- Lead developer
- Stanford Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**CD19-CD22 CAR-T** is a nonspecific, target-defined category of engineered T-cell therapies rather than one uniquely identifiable drug product. These autologous or potentially allogeneic CAR-T-cell products are designed to recognize **B-lymphocyte antigen CD19** and **B-lymphocyte antigen CD22**, two surface antigens commonly expressed by malignant B cells. Dual targeting is intended to improve antitumor activity and reduce relapse caused by loss or downregulation of either single antigen. Multiple distinct CD19-CD22 CAR-T programs have been evaluated clinically for relapsed or refractory B-cell acute lymphoblastic leukemia and B-cell lymphomas, including diffuse large B-cell lymphoma and central nervous system lymphoma.
- Other names
- CD19 and CD22 CAR-T cellsCD-19 and CD22 CAR-T cellsCD 19 and CD22 CAR-T cellsCD19-CD22 CAR+ T cellsCD19-CD22 CAR-T cellsCD-19-CD22 CAR-T cellsCD 19-CD22 CAR-T cellsCD19/CD22 CAR-T cellsHuman CD19-CD22 Targeted T Cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CD19-CD22 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-CD22 CAR-T.